Predict your next investment

Novellus company logo
HEALTHCARE | Biotechnology
novellus.bio

See what CB Insights has to offer

Business Relationships

4

Novellus Partners & Customers

4 Partners and customers

Novellus has 4 strategic partners and customers. Novellus recently partnered with Plexxikon on June 6, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

6/3/2020

Licensor

Plexxikon

United States

Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394, Plexxikon’s Next-Generation, Clinical Stage BRAF Inhibitor

BERKELEY , Calif. & JERUSALEM -- -- Novellus , a precision-oncology drug development company , announced today that it has entered into an exclusive worldwide license agreement with Plexxikon , a member of the Daiichi Sankyo Group , for PLX8394 , its clinical-stage oncology drug candidate which targets the BRAF protein .

2

9/3/2018

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

9/3/2018

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

1/30/2017

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/3/2020

9/3/2018

9/3/2018

1/30/2017

Type

Licensor

Licensee

Partner

Partner

Business Partner

Plexxikon

Country

United States

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Novellus Executes Exclusive Worldwide License Agreement with Plexxikon for PLX8394, Plexxikon’s Next-Generation, Clinical Stage BRAF Inhibitor

BERKELEY , Calif. & JERUSALEM -- -- Novellus , a precision-oncology drug development company , announced today that it has entered into an exclusive worldwide license agreement with Plexxikon , a member of the Daiichi Sankyo Group , for PLX8394 , its clinical-stage oncology drug candidate which targets the BRAF protein .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.